A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP)
in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancer